ArticleFrontiers in oncology2026
Clinical efficacy of
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the clinical value of Methods: A total of 115 patients who underwent percutaneous lung aspiration biopsy at Suining Central Hospital from September 2019 to December 2020 were included. Patients were assigned to either the Results: Baseline characteristics were comparable between groups (all p > 0.05). The SPECT/CT-guided group achieved 100% diagnostic accuracy, outperforming the CBCT-guided group (93.83%). Higher TBR ratios on SPECT/CT were strongly predictive of malignancy (AUC = 1.0, ICC = 0.938). For mass-type lesions 3-3.99 cm in diameter, SPECT/CT guidance yielded significantly higher accuracy than CBCT (p = 0.027, Posterior Probability of Superiority >96%). No significant accuracy differences were observed in other lesion locations, except for superior results in the left lower lobe with SPECT/CT. Complication rates were similar (23.53% vs. 16.05%, p > 0.05). Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.